Skin Cancer

Laura Rezac, MD and her colleagues evaluated a teledermatology postoperative follow-up model after Mohs Micrographic surgery.

Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.

The question was a conversation starter after an ACMS clinical abstract presentation.

An ACMS poster session delves into the role artificial intelligence can play in the treatment of basal cell carcinoma.

A poster session and ACMS keynote speaker Anant Madabhushi, MS, PhD, both delve into the use of AI in Mohs surgery.

Bar will share insight on foldover interpolated flaps for full thickness of nasal defects.

The ACMS president and scientific program chair share opportunities to discover innovations in Mohs surgery during this weekend’s meeting.

May is National Skin Cancer and Melanoma Awareness Month. We have skin cancer at the forefront of our coverage this month. Here is a recap of the latest news about skin cancer research, studies, and more.

Using mass spectrometry, researchers examined novel changes to gather updated metastasis information.

The results of a new study reveal that the the antibody works by activating the immune response to fight cancer and slows melanoma growth in mice.

From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.

Researchers identified several dermoscopic features associated with genes LINC00518, PRAME, and TERT.

Researchers said responses may depend on prior immunotherapy.

Data from the KEYNOTE-942 trial was presented at the American Association for Cancer Research Annual Meeting 2023.

Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.

The PD-1 inhibitor pembrolizumab has proven its efficacy in a number of different cancers.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

A new survey found that the demographics are not following safe sun habits and have low skin cancer awareness.

Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.

In a recent review, authors explored the effects of targeted therapies and immune checkpoint inhibitors on melanoma, particularly in minimal residual disease.

With the advent of immunotherapy, the 1-year survival rate for patients with metastatic melanoma has increased from 25% to 50%.

Patients in the clinical trial had confirmed disease progression after 12 weeks.

Researchers said the pandemic played a role in healthcare providers’ ability to safely and promptly treat various skin cancers.

There are currently no FDA approved therapies in this treatment setting.

The UK and Netherlands study assessed tumor response rates among 91 patients.